BEIJING — Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceuticals in China, announced that its COVID-19 vaccine (CoronaVac) has been approved through the Brazilian Health Regulatory Agency (Anvisa) for emergency use in youth ages 3 to 5 on July 13. These young people will get the same dose that is already implemented for minors from 6 to 17 years old and adults and there are no restrictions on the application for immunocompromised young people over 3 years old. to five years.
This approval was given as part of comprehensive evaluations based on the effects of studies of all knowledge about the vaccine and its use in children. Analysis based on data presented through the Butantan Institute, with knowledge of studies from Chile, where the vaccine is already used in this age group, studies effects on Covid-19 vaccination in Brazil, reviews of invited medical societies, genuine and published evidence from the clinical literature.
Participating in this evaluation activity were the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Infectious Diseases (SBI), the Brazilian Society of Pneumology and Physiology (SBPT), the Brazilian Society of Vaccines (SBIm) and the Brazilian Association of Collective Health Diseases (Abrasco). To assist Anvisa in the comparison of the vaccine, technicians from the above-mentioned establishments had technical knowledge and studies on the vaccine.
CoronaVac is legal for emergency use for adults in Brazil from January 17, 2021. Subsequently, Anvisa legalized the extension of the use of the vaccine to young people and adolescents over 6 to 17 years old on January 20, 2022.
As of July 14, 2022, CoronaVac is legal for emergency use for minors in 14 countries and regions, Chile, Colombia, Ecuador, Brazil, and countries and regions in Asia and Africa.
About SINOVAC
Sinovac Biotech Ltd. , (SINOVAC) is a biopharmaceutical company based in China in R
SINOVAC product portfolio vaccines against COVID-19, hand-foot-mouth disease (HFMD) inflamed with enterovirus 71 (EV71), hepatitis A and B, seasonal influenza, pneumococcal disease, pandemic influenza H5N1 (avian influenza), influenza H1N1 (swine influenza influenza), chickenpox, mumps and polio.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions around the world. Healive’s® hepatitis A vaccine met WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is a cutting-edge vaccine announced in China in 2016. In 2022, Sivac’s inactivated Sabin strain polio vaccine (sIPV) was prequalified through WHO.
SINOVAC, the first company to gain approval for its Panflu. 1® H1N1 influenza vaccine, which provided the Chinese government’s vaccination crusade and storage program. The Company is also the sole supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government’s storage program.
SINOVAC is frequently committed to the studies and progression of new vaccines, with more combination vaccine products in its portfolio, and is constantly exploring the opportunities of the global market. SINOVAC plans to carry out more extensive and in-depth exchanges and cooperation with other countries and advertising and advertising organizations.
For more information, visit the company’s online page on www. sinovac. com.
See the businesswire. com edition: https://www. businesswire. com/news/home/20220714005372/en/
Contacts
Sinovac Biotech Ltd. pr@sinovac. com Public Relations Team
ICR Inc. Bill Zima USA: 1-646-308-1707 william. zima@icrinc. com
#distro
Sign up for the most productive stories from Financial Post, a department of Postmedia Network Inc.
A welcome email is on the way. If you don’t see it, check your spam folder.
The next Financial Post Top Stories factor will soon be in your inbox.
We found a challenge with your registration. Check back
Postmedia is committed to maintaining a civilized discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to moderate before appearing on the site. We ask that you keep your comments applicable and respectful. I’ve enabled email notifications. You will now receive an email if you get a response to your comment, if there is an update to a comment thread you are following, or if a user follows your comments. See our network rules for more information and main points on how to adjust your email settings.
365 Bloor Street East, Toronto, ONTARIO M4W 3L4
© 2022 Financial Post, a department of Postmedia Network Inc. All rights reserved. Unauthorized broadcasting, transmission or transmission is strictly prohibited.
This uses cookies to personalize your content (including ads) and allows us to analyze our traffic. Learn more about cookies here. By continuing to use our Array, you agree to our terms of use and privacy policy.